CCL19 and CCL21, as well as their common receptor the CCR7, appear to be important factors not only in the initiation of the CNS pathology during the early stage of MS, but also in the regulation of the inflammatory response, and seem to be interesting targets for future therapeutic interventions. This evidence concerns the gene CCL19 and myeloid sarcoma.